We're currently experiencing phone and Internet issues in our call center, which may result in dropped calls or extended wait times. We're sorry for the inconvenience and are working to get it resolved as quickly as possible.
Sorry, we do not offer this product as it requires refrigeration during shipping.
(pem'' broe liz' ue mab)[Posted 08/31/2017] AUDIENCE: Oncology ISSUE: Based on data from two recently halted clinical trials, the U.S. Food and Drug Administration today is issuing this statement to inform the public, health care professionals, and oncology clinical investigators about the risks associated with the use of pembrolizumab (Keytruda) in combination with dexamethasone and an immunomodulatory agent (lenalidomide or pomalidomide) for the treatment of patients with multiple myeloma. Pembrolizumab is not approved for treatment of multiple myeloma. The FDA statement is based on review of data from two clinical trials (KEYNOTE-183 and KEYNOTE-185) evaluating the use of pembrolizumab combined with other treatments in patients with multiple myeloma. On July 3, 2017, the FDA required that all patients in these trials be discontinued from further investigation with this drug, because interim results from both trials demonstrated an increased risk of death for patients receiving pembrolizumab when it was combined with an immunomodulatory agent as compared to the control group (see statistical analysis section below). Merck & Co., Inc. was made aware of the issue through an external data monitoring committee recommendation and suspended the trials to enrollment on June 12, 2017. BACKGROUND: This does not apply to patients taking pembrolizumab for an approved indication. Patients on pembrolizumab for an approved use should continue to take their medication as directed by their health care professional. Pembrolizumab is currently approved by the FDA for treatment of: Melanoma, Lung Cancer, Head and Neck Cancer, Classical Hodgkin Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High (MSI-H) Cancer. For a summary of the statistical analysis and findings, please refer to the FDA Statement, available at: http://bit.ly/2iJ0du7. RECOMMENDATION: Other multiple myeloma clinical trials of pembrolizumab, other PD-1/PD-L1 cancer drugs and other combinations are currently undergoing clinical evaluation. The FDA will be working directly with sponsors of pembrolizumab and other PD-1/PD-L1 cancer drugs, as well as clinical investigators conducting clinical trials in patients with multiple myeloma, to determine the extent of the safety issue. The agency will communicate any new information to the public as soon as it is able.